169 related articles for article (PubMed ID: 26267517)
1. Activating Mutations in PIK3CA Lead to Widespread Modulation of the Tyrosine Phosphoproteome.
Zahari MS; Wu X; Blair BG; Pinto SM; Nirujogi RS; Jelinek CA; Malhotra R; Kim MS; Park BH; Pandey A
J Proteome Res; 2015 Sep; 14(9):3882-3891. PubMed ID: 26267517
[TBL] [Abstract][Full Text] [Related]
2. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL; Askham JM; Knowles MA
Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
[TBL] [Abstract][Full Text] [Related]
4. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
5. Activation of diverse signalling pathways by oncogenic PIK3CA mutations.
Wu X; Renuse S; Sahasrabuddhe NA; Zahari MS; Chaerkady R; Kim MS; Nirujogi RS; Mohseni M; Kumar P; Raju R; Zhong J; Yang J; Neiswinger J; Jeong JS; Newman R; Powers MA; Somani BL; Gabrielson E; Sukumar S; Stearns V; Qian J; Zhu H; Vogelstein B; Park BH; Pandey A
Nat Commun; 2014 Sep; 5():4961. PubMed ID: 25247763
[TBL] [Abstract][Full Text] [Related]
6. Chronic Cigarette Smoke Mediated Global Changes in Lung Mucoepidermoid Cells: A Phosphoproteomic Analysis.
Solanki HS; Advani J; Khan AA; Radhakrishnan A; Sahasrabuddhe NA; Pinto SM; Chang X; Prasad TSK; Mathur PP; Sidransky D; Gowda H; Chatterjee A
OMICS; 2017 Aug; 21(8):474-487. PubMed ID: 28816646
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
8. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways.
Carvalho CR; Carvalheira JB; Lima MH; Zimmerman SF; Caperuto LC; Amanso A; Gasparetti AL; Meneghetti V; Zimmerman LF; Velloso LA; Saad MJ
Endocrinology; 2003 Feb; 144(2):638-47. PubMed ID: 12538627
[TBL] [Abstract][Full Text] [Related]
9. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteome analyses identify PrfA-responsive proteins and phosphoproteins in Listeria monocytogenes.
Misra SK; Moussan Désirée Aké F; Wu Z; Milohanic E; Cao TN; Cossart P; Deutscher J; Monnet V; Archambaud C; Henry C
J Proteome Res; 2014 Dec; 13(12):6046-57. PubMed ID: 25383790
[TBL] [Abstract][Full Text] [Related]
11. Identification of major ERK-related phosphorylation sites in Gab1.
Lehr S; Kotzka J; Avci H; Sickmann A; Meyer HE; Herkner A; Muller-Wieland D
Biochemistry; 2004 Sep; 43(38):12133-40. PubMed ID: 15379552
[TBL] [Abstract][Full Text] [Related]
12. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
[TBL] [Abstract][Full Text] [Related]
13. Global redox proteome and phosphoproteome analysis reveals redox switch in Akt.
Su Z; Burchfield JG; Yang P; Humphrey SJ; Yang G; Francis D; Yasmin S; Shin SY; Norris DM; Kearney AL; Astore MA; Scavuzzo J; Fisher-Wellman KH; Wang QP; Parker BL; Neely GG; Vafaee F; Chiu J; Yeo R; Hogg PJ; Fazakerley DJ; Nguyen LK; Kuyucak S; James DE
Nat Commun; 2019 Dec; 10(1):5486. PubMed ID: 31792197
[TBL] [Abstract][Full Text] [Related]
14. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
15. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
[TBL] [Abstract][Full Text] [Related]
16. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
[TBL] [Abstract][Full Text] [Related]
17. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
18. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
19. Research resource: identification of novel growth hormone-regulated phosphorylation sites by quantitative phosphoproteomics.
Ray BN; Kweon HK; Argetsinger LS; Fingar DC; Andrews PC; Carter-Su C
Mol Endocrinol; 2012 Jun; 26(6):1056-73. PubMed ID: 22570334
[TBL] [Abstract][Full Text] [Related]
20. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
